[go: up one dir, main page]

AR008025A1 - Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina - Google Patents

Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina

Info

Publication number
AR008025A1
AR008025A1 ARP980102879A ARP980102879A AR008025A1 AR 008025 A1 AR008025 A1 AR 008025A1 AR P980102879 A ARP980102879 A AR P980102879A AR P980102879 A ARP980102879 A AR P980102879A AR 008025 A1 AR008025 A1 AR 008025A1
Authority
AR
Argentina
Prior art keywords
thiazolidindiona
pharmaceutical combination
insulin
insulin secretogogue
sensitizer
Prior art date
Application number
ARP980102879A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR008025(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712854.0A external-priority patent/GB9712854D0/en
Priority claimed from GBGB9806710.1A external-priority patent/GB9806710D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR008025A1 publication Critical patent/AR008025A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de un sensibilizador a la insulina para la preparación de un medicamento útil para el tratamiento de diabetes mellitus y procesosasociados a la diabetes mellitus en un mamífero, que comprende una cantidad eficaz no tóxica y farmcéuticamente eficaz de un sensibilizador a la insulinay un secretagogo de insulina; y una composición farmacéutica que comprende dicho sensibilizador.
ARP980102879A 1997-06-18 1998-06-17 Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina AR008025A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712854.0A GB9712854D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806710.1A GB9806710D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
AR008025A1 true AR008025A1 (es) 1999-12-09

Family

ID=26311744

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980102881A AR012996A1 (es) 1997-06-18 1998-06-17 Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.
ARP980102879A AR008025A1 (es) 1997-06-18 1998-06-17 Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980102881A AR012996A1 (es) 1997-06-18 1998-06-17 Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.

Country Status (33)

Country Link
EP (3) EP0999845B1 (es)
JP (1) JP2001523270A (es)
KR (3) KR20080011356A (es)
CN (1) CN1168451C (es)
AP (1) AP1600A (es)
AR (2) AR012996A1 (es)
AT (1) ATE353654T1 (es)
AU (1) AU8539298A (es)
BG (2) BG64817B1 (es)
BR (1) BR9810142A (es)
CA (1) CA2294385C (es)
CO (1) CO4940457A1 (es)
CZ (1) CZ299310B6 (es)
DE (1) DE69837089T2 (es)
DZ (1) DZ2522A1 (es)
EA (1) EA003025B1 (es)
ES (1) ES2283064T3 (es)
ID (1) ID24065A (es)
IL (1) IL133137A (es)
IN (1) IN189319B (es)
MA (1) MA24571A1 (es)
MY (1) MY125855A (es)
NO (3) NO326263B1 (es)
NZ (1) NZ501163A (es)
OA (1) OA11510A (es)
PE (1) PE108199A1 (es)
PL (2) PL337510A1 (es)
SK (1) SK286028B6 (es)
TR (1) TR199903096T2 (es)
TW (1) TW542717B (es)
UA (1) UA67743C2 (es)
UY (1) UY25048A1 (es)
WO (1) WO1998057649A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CA2370258A1 (en) 1999-04-23 2000-11-02 Paul David James Blackler Thiazolidinedione derivative and its use as antidiabetic
AU1452601A (en) 1999-11-01 2001-05-14 Wisconsin Alumni Research Foundation Cholesterol transport gene
BRPI0206432A2 (pt) 2001-01-12 2016-10-25 Sun Pharmaceutical Ind Ltd métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento
KR100698595B1 (ko) * 2003-09-29 2007-03-21 보령제약 주식회사 무정형 또는 준결정형 글리메피리드, 이의 제조방법 및 무정형 또는 준결정형 글리메피리드를 포함하는 약학적조성물
CN1874774B (zh) 2003-10-31 2011-04-13 武田药品工业株式会社 包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂
AR058605A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Preparacion solida
CN104158867B (zh) * 2014-08-06 2017-05-17 电子科技大学 一种基于wave协议的信息多跳转发方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
FI904414A7 (fi) 1988-03-08 1990-09-07 Pfizer Tiatsolidiinidioni-hypoglykeemisesti vaikuttavat aineet
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
EP0533933A4 (en) 1990-07-03 1993-05-05 Yamanouchi Pharmaceutical Co. Ltd. Bisheterocyclic compound
ATE116971T1 (de) 1990-08-23 1995-01-15 Pfizer Hypoglykämische hydroxyharnstoffderivate.
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−2,4−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
ATE202352T1 (de) 1991-04-11 2001-07-15 Upjohn Co Thiazolidindionderivate, herstellung und anwendung
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
TW222626B (es) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO1993003724A1 (en) * 1991-08-26 1993-03-04 The Upjohn Company Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
JPH07505647A (ja) 1992-04-10 1995-06-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 複素環化合物および2型糖尿病の治療におけるそれらの使用
WO1993022445A1 (en) 1992-05-05 1993-11-11 The Upjohn Company A process for producing pioglitazone metabolite
DE69331010D1 (de) 1992-07-03 2001-11-29 Smithkline Beecham Plc Benzoxazol- und benzothiazol-derivate als arzneimittel
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
OA11510A (en) 2004-02-03
AP1600A (en) 2006-04-28
AR012996A1 (es) 2000-11-22
HK1028200A1 (en) 2001-02-09
NO2009002I1 (no) 2009-03-02
EA200000039A1 (ru) 2000-08-28
EP2266576A1 (en) 2010-12-29
CO4940457A1 (es) 2000-07-24
PE108199A1 (es) 2000-01-14
MA24571A1 (fr) 1998-12-31
BG64817B1 (bg) 2006-05-31
TR199903096T2 (xx) 2000-08-21
EA003025B1 (ru) 2002-12-26
PL198018B1 (pl) 2008-05-30
NO326263B1 (no) 2008-10-27
UY25048A1 (es) 2000-09-29
CZ9904577A3 (en) 2001-05-16
AP9901717A0 (en) 1999-12-31
NO20083276L (no) 2000-02-17
WO1998057649A1 (en) 1998-12-23
CN1260719A (zh) 2000-07-19
BG109397A (bg) 2006-05-31
MY125855A (en) 2006-08-30
UA67743C2 (uk) 2004-07-15
DE69837089T2 (de) 2007-06-21
ATE353654T1 (de) 2007-03-15
EP1671637A2 (en) 2006-06-21
NO996264D0 (no) 1999-12-17
BG104058A (en) 2000-10-31
TW542717B (en) 2003-07-21
KR20070011651A (ko) 2007-01-24
CA2294385C (en) 2007-06-05
EP1671637A3 (en) 2007-12-19
KR20010013840A (ko) 2001-02-26
CZ299310B6 (cs) 2008-06-18
DE69837089D1 (de) 2007-03-29
SK286028B6 (sk) 2008-01-07
BR9810142A (pt) 2000-08-08
JP2001523270A (ja) 2001-11-20
IN189319B (es) 2003-02-08
EP0999845A1 (en) 2000-05-17
ES2283064T3 (es) 2007-10-16
EP0999845B1 (en) 2007-02-14
AU8539298A (en) 1999-01-04
DZ2522A1 (fr) 2003-02-01
KR20080011356A (ko) 2008-02-01
SK179199A3 (en) 2000-11-07
PL337510A1 (en) 2000-08-28
CA2294385A1 (en) 1998-12-23
ID24065A (id) 2000-07-06
IL133137A0 (en) 2001-03-19
CN1168451C (zh) 2004-09-29
NO996264L (no) 2000-02-17
IL133137A (en) 2004-02-08
NZ501163A (en) 2002-02-01

Similar Documents

Publication Publication Date Title
AR012998A1 (es) Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprende dichosensibilizador y dicho agente.
MY124695A (en) Novel composition and use.
DK372786D0 (da) Farmaceutiske praeparater af phenindamin
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
BR9810445A (pt) Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e diguanida
AR008025A1 (es) Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina
UY25798A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
AR012997A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene.
AR019724A2 (es) Composicion farmaceutica util para el tratamiento de diabetes mellitus y condiciones asociadas
AR016768A1 (es) COMPOSICIoN FARMACÉUTICA DE 5-(4- (2-(N-METIL-N-(2-PIRIDIL) AMINO)ETOXI)BENCIL)TIAZOLIDIN-2-4-DIONA Y UN SECRETAGOGO DE INSULINA Y USO DE LA MISMA PARA PREPARACIoN DE MEDICAMENTOS
AR013352A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica.
TR200101336T2 (tr) Bir-beta-agonisti ile başka bir antidiyabetik madde içeren kombinasyonlar
ECSP982593A (es) Nuevo metodo de tratamiento vi
ES2188232T3 (es) Uso de cetirizina para impedir la aparicion del asma.
WO2001047509A3 (en) Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
ECSP993215A (es) Nueva composicion y uso
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
ECSP982535A (es) Nuevo metodo de tratamiento (i)
ECSP982534A (es) Nuevo metodo de tratamiento
BR0309375A (pt) Tratamento de sìndrome metabólica
ECSP982542A (es) Nuevo metodo de tratamiento iii
CO5270004A1 (es) Composiciones farmaceuticas con agente del tipo biguanida para tratamientos en diabetes
ECSP993216A (es) Nueva composicion y uso ii
ECSP982592A (es) Nuevo metodo de tratamiento v

Legal Events

Date Code Title Description
FC Refusal